Inhibitor shows lasting structural integrity and long terminal half-life in tumor tissue
Omomyc is a first in class MYC inhibitor that targets the MYC oncogene which is deregulated in most tumor types. This therapeutic mini-protein was developed in-house by the Vall d'Hebron Institute of Oncology (VHIO) and the ...
Feb 20, 2023
0
2